Autologous CAR-T Cells Targeting B7-H3 in PDAC
Phase 1
27
about 4 years
18+
1 site in NC
What this study is about
This trial is testing a new treatment called iC9.CAR.B7-H3 T cell infusion to see if it's safe and well-tolerated for people with pancreatic cancer that has returned after standard treatment. This treatment involves using your own immune cells (T cells) modified to target the B7-H3 antigen.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive iC9-CAR.B7-H3 T cell infusion
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
infusion
Primary: Cytokine Release Syndrome, Number of participants with adverse event
Secondary: Definition of Dose Limiting Toxicity, Objective response rate (ORR)- bridging therapy, Objective response rate- no bridging therapy, Overall Survival (OS), Progression Free Survival (PFS), The disease control rate (DCR)
Oncology